{
    "nct_id": "NCT00404495",
    "official_title": "Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease.\n* Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization \\[WHO\\] grade 3 or 4)\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Diagnosis of brainstem glioma\n* Concurrent administration of any other anti-tumor therapy\n* Pre-existing uncontrolled diarrhea\n\nsex: ALL\n\nminimumAge: 6 Months\n\nmaximumAge: 18 Years\n\nstdAges: ['CHILD', 'ADULT']",
        "inclusion": "* Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease.\n* Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3 or 4)\n* Life expectancy ≥ 3 months\n\nsex: ALL\n\nminimumAge: 6 Months\n\nmaximumAge: 18 Years\n\nstdAges: ['CHILD', 'ADULT']",
        "exclusion": "* Diagnosis of brainstem glioma\n* Concurrent administration of any other anti-tumor therapy\n* Pre-existing uncontrolled diarrhea"
    }
}